Many months after COVID-19 vaccines were first authorized for public use, still limited supplies could only partially reduce the devastating loss of life and economic costs caused by the pandemic. Could additional vaccine doses have been manufactured more quickly some other way? Would...

The COVID-19 pandemic has revealed that a true, end-to-end research and development (R&D) and response ecosystem—meaning, one that develops, produces, and delivers needed vaccines to global populations in a rapid and equitable fashion—remains an elusive goal. This report is comprised of 3...